Search research articles
Contact Us
Filters
Showing results (31-40 of 111) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 1992
High-dose busulfan in patients with myeloma
J Mansi, F da Costa, C Viner, et al.
British Journal of Cancer
|
October 1, 1990
The value of computed tomographic (CT) scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer
J Hardy, I Smith, G Cherryman, et al.
Cancer Chemotherapy and Pharmacology
|
July 8, 1998
Phase I study of oral JM216 given twice daily
P Beale, F Raynaud, J Hanwell, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
June 25, 2004
Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998
L Livi, E Andreopoulou, N Shah, et al.
British Journal of Cancer
|
March 20, 2008
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
H-T Arkenau, D Olmos, J E Ang, et al.
Journal of Molecular Evolution
|
February 25, 2012
Nucleotide composition of CO1 sequences in Chelicerata (Arthropoda): detecting new mitogenomic rearrangements
Juliette Arabi, Mark L I Judson, Louis Deharveng, et al.
Gynecologic Oncology
|
October 27, 2006
Participation of patients with gynecological cancer in phase I clinical trials: two years experience in a major cancer center
F Legge, D Eaton, R Molife, et al.
Oncology Reports
|
May 20, 2011
Antitumor effect of trimelamol against human breast carcinoma xenografts in nude mice
Y Yamada, T Kubota, Y Hoshiya, et al.
Cancer Chemotherapy and Pharmacology
|
June 10, 1998
Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients
P Beale, I Judson, J Hanwell, et al.
Cancer Chemotherapy and Pharmacology
|
December 4, 2009
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
M Ranson, H Shaw, J Wolf, et al.
Page
of 12
Search research articles
Search
Showing results (31-40 of 111) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 1992
High-dose busulfan in patients with myeloma
J Mansi, F da Costa, C Viner, et al.
British Journal of Cancer
|
October 1, 1990
The value of computed tomographic (CT) scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer
J Hardy, I Smith, G Cherryman, et al.
Cancer Chemotherapy and Pharmacology
|
July 8, 1998
Phase I study of oral JM216 given twice daily
P Beale, F Raynaud, J Hanwell, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
June 25, 2004
Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998
L Livi, E Andreopoulou, N Shah, et al.
British Journal of Cancer
|
March 20, 2008
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
H-T Arkenau, D Olmos, J E Ang, et al.
Journal of Molecular Evolution
|
February 25, 2012
Nucleotide composition of CO1 sequences in Chelicerata (Arthropoda): detecting new mitogenomic rearrangements
Juliette Arabi, Mark L I Judson, Louis Deharveng, et al.
Gynecologic Oncology
|
October 27, 2006
Participation of patients with gynecological cancer in phase I clinical trials: two years experience in a major cancer center
F Legge, D Eaton, R Molife, et al.
Oncology Reports
|
May 20, 2011
Antitumor effect of trimelamol against human breast carcinoma xenografts in nude mice
Y Yamada, T Kubota, Y Hoshiya, et al.
Cancer Chemotherapy and Pharmacology
|
June 10, 1998
Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients
P Beale, I Judson, J Hanwell, et al.
Cancer Chemotherapy and Pharmacology
|
December 4, 2009
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
M Ranson, H Shaw, J Wolf, et al.
Page
of 12